Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Application
DCZ0415 may be used to determine its effects on cell viability, cell cycle distribution, invasive capabilities, and migratory behavior of colorectal cancer (CRC) cells.
Biochem/physiol Actions
DCZ0415 also reduces cyclin D1, β-catenin, and T-cell factor 1 levels, resulting in the inactivation of the Wnt/β-catenin pathway.
DCZ0415 is a TRIP13 inhibitor that exhibits antimyeloma activity in cultures (IC50 in µM = 1.15/U266, 3.25/ARK, 4.13/OCI-MY5, 5.12/ARP-1, 7.4/RPMI-8226, H292/8.02) and in xenograft models in vivo (25 or 50 mg/kg via daily i.p. to mice with MOPC-315 or H929 tumors, respectively) by impairing nonhomologous end-joining (NHEJ) repair and NF-kB activity. Synergistic antimyeloma activity is observed when DCZ0415 is used in combination with the DNA-akylating agent melphalan or the HDAC inhibitor panobinostat.
存储类别
11 - Combustible Solids
闪点 (F)
Not applicable
闪点 (°C)
Not applicable